Trial Holdings Inc. (141A) AI Stock Analysis

• Market Cap: ¥321.13B
• Dividend Yield: 0.62%
• Average Volume (3M): 2.39M
• Price to Earnings (P/E): 26.8
• Beta (1Y): 0.22
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 6,529
• Sector: Consumer Defensive
• Sector Strength: 50
• Industry: Discount Stores
• EPS (TTM): 27.62
• Shares Outstanding: 122,382,900
• 10 Day Avg. Volume: 3,036,170
• 30 Day Avg. Volume: 2,385,083
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥3,166.00
• Price Target Upside: 26.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 71 Outperform
• Price Target: ¥3,166.00 ▲(26.24% Upside)

The overall stock score is primarily driven by strong technical analysis indicators, suggesting positive market momentum. However, the high valuation and cash flow challenges weigh on the score, indicating potential risks. The company's financial performance is stable, but improvements in profitability and cash flow management are necessary for a higher score.

Trial Holdings Inc. Business Overview & Revenue Model

Company Description

Trial Holdings Inc. (141A) is a diversified holding company primarily engaged in the healthcare and biotechnology sectors. The company focuses on developing innovative solutions for clinical trials, including data management, patient recruitment, and regulatory compliance. Trial Holdings also invests in emerging biotech firms, providing them with necessary resources and expertise to accelerate drug development and bring new therapies to market.

How the Company Makes Money

Trial Holdings Inc. generates revenue through several key streams. Primarily, the company earns income from its clinical trial services, which include consulting fees for data management and patient recruitment. Additionally, Trial Holdings receives revenue from its investments in biotech firms, taking equity stakes in companies with promising drug candidates. These investments often yield returns through successful exits, either via public offerings or acquisitions. The company also benefits from strategic partnerships with pharmaceutical companies, which may involve joint ventures or collaborative projects that provide a share of profits from successful drug development.

Trial Holdings Inc. Financial Statement Overview

Summary

Trial Holdings Inc. shows strong revenue growth and operational efficiency, but profitability and cash flow management need improvement. The balance sheet remains robust, though increasing debt levels require attention. Overall, the company is on a stable trajectory but must address cash flow challenges to ensure long-term financial health.

Income Statement

Trial Holdings Inc. has demonstrated consistent revenue growth over the years, with a recent growth rate of 2.96%. The gross profit margin has improved to 20.78%, indicating efficient cost management. However, the net profit margin remains relatively low at 1.46%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are stable, reflecting operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has increased to 0.31, indicating a moderate level of leverage. Return on equity is strong at 9.32%, showcasing effective use of shareholder funds. The equity ratio stands at 42.00%, suggesting a solid capital structure. However, the increase in total debt warrants careful monitoring.

Cash Flow

The cash flow situation is concerning, with negative operating and free cash flows in the latest period. The free cash flow growth rate is negative, indicating cash flow challenges. The operating cash flow to net income ratio is negative, highlighting potential liquidity issues. Improvement in cash flow management is necessary.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	783.41B	806.59B	720.44B	655.48B	597.69B	157.93B
Gross Profit	158.78B	167.60B	144.84B	117.53B	103.49B	26.32B
EBITDA	30.34B	33.74B	30.78B	25.03B	21.58B	5.42B
Net Income	10.32B	11.75B	11.44B	8.08B	7.13B	1.85B
Balance Sheet
Total Assets	271.07B	300.28B	283.63B	200.64B	185.73B	171.44B
Cash, Cash Equivalents and Short-Term Investments	47.56B	72.33B	91.95B	23.90B	27.43B	22.74B
Total Debt	12.85B	38.58B	16.14B	19.61B	24.44B	27.94B
Total Liabilities	145.57B	171.25B	165.44B	132.62B	126.02B	118.65B
Stockholders Equity	122.67B	126.13B	115.68B	65.89B	57.96B	51.47B
Cash Flow
Free Cash Flow	0.00	-38.41B	36.84B	1.70B	9.39B	-7.14B
Operating Cash Flow	0.00	-4.45B	59.50B	18.45B	22.34B	-2.94B
Investing Cash Flow	0.00	-35.89B	-26.00B	-16.77B	-13.49B	-4.72B
Financing Cash Flow	0.00	20.77B	34.50B	-5.19B	-4.32B	-1.34B

Trial Holdings Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2508.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:141A, the sentiment is Neutral. The current price of 2508 is below the 20-day moving average (MA) of 2549.50, above the 50-day MA of 2475.88, and above the 200-day MA of 2441.08, indicating a neutral trend. The MACD of 55.82 indicates Positive momentum. The RSI at 48.09 is Neutral, neither overbought nor oversold. The STOCH value of 23.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:141A.

Trial Holdings Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7646	74 Outperform	¥12.97B	40.46		3.54%	-1.53%	48.90%
141A	71 Outperform	¥321.13B	26.76		0.62%	―	―
7451	68 Neutral	¥274.72B	11.47		2.94%	1.49%	6.34%
3080	67 Neutral	¥8.99B	37.92		1.86%	-2.46%	-58.62%
8203	66 Neutral	¥28.35B	10.06		2.67%	6.32%	10.30%
2264	63 Neutral	¥306.12B	41.10		2.60%	2.97%	-46.46%
Sector *	63 Neutral	$20.42B	14.64	-2.96%	3.11%	2.04%	-6.12%

Trial Holdings Inc. Corporate Events

Trial Holdings Inc. Reports Steady Growth and Expansion

Trial Holdings Inc. reported a steady growth in sales and customer traffic, with notable performance in both food and non-food categories. The company expanded its store network with four new openings and no closures in June. Despite weather challenges and fewer holidays affecting sales slightly, the company maintained a robust market position with strong sales in seasonal products and ready meals.

TRIAL Holdings Completes Acquisition of Seiyu Co., Ltd.

TRIAL Holdings, Inc. has successfully completed the acquisition of Seiyu Co., Ltd., making it a wholly owned subsidiary as of July 1, 2025. This acquisition marks a significant expansion for TRIAL Holdings, as Seiyu operates a retail chain selling groceries, apparel, and household goods. The consolidation of Seiyu into TRIAL’s financial statements will begin in the fiscal year ending June 2026, with earnings forecasts to be disclosed later, indicating a strategic move to strengthen its market position.

TRIAL Holdings Secures Loan for Seiyu Acquisition

TRIAL Holdings, Inc. has announced the execution of a loan agreement with financial covenants to fund the acquisition of Seiyu Co., Ltd., making it a wholly owned subsidiary. The loan, amounting to 367.4 billion yen from MUFG Bank, Ltd., is unsecured and scheduled for a one-year repayment. This strategic acquisition is expected to enhance TRIAL Holdings’ market positioning, although the financial impact will be reflected in the fiscal period ending June 2026.

Trial Holdings Inc. Reports Continued Sales Growth and Store Expansion

Trial Holdings Inc. reported a consistent increase in sales and customer traffic, with a notable 48-month streak of same-store sales growth. The company has been expanding its store count, opening three new locations in May while closing one. The introduction of measures to improve gross profit has positively impacted customer traffic and average spending, indicating a strong operational performance. Favorable weather conditions during the first half of Golden Week contributed to increased sales in non-food categories such as DIY tools and home appliances.

TRIAL Holdings Stock Gains Loan Margin Trading Status

TRIAL Holdings, Inc. announced that its stock has been newly selected as a Loan Margin Trading Issue on the Tokyo Stock Exchange Growth Market, effective June 3, 2025. This designation is expected to enhance liquidity, improve the supply-demand balance, and contribute to more active trading and fairer pricing of the company’s stock.

TRIAL Holdings Reports Increased Sales but Declining Profits

TRIAL Holdings, Inc. reported consolidated financial results for the nine months ending March 31, 2025, showing a significant increase in net sales by 11.7% year-on-year. However, the company experienced a decline in operating profit by 12.6% and ordinary profit by 10.4%, indicating challenges in maintaining profitability despite increased sales. The equity-to-asset ratio improved to 45.3% from 40.8% as of June 2024, reflecting a stronger financial position. The company also revised its earnings forecast for the fiscal year ending June 2025, projecting a slight increase in net sales and operating profit but a decrease in profit attributable to owners of the parent by 9.1%.

TRIAL Holdings Revises FY2025 Financial Forecast Amid Challenging Conditions

TRIAL Holdings, Inc. has revised its financial forecast for the fiscal year ending June 30, 2025, due to recent performance trends. The company expects a decrease in net sales and profits compared to previous forecasts, influenced by unexpected weather conditions affecting seasonal products and increased expenses from new store openings and higher part-time wages. Despite these adjustments, the dividend forecast remains unchanged.

TRIAL Holdings Inc. Reports Strong Sales Growth and Store Expansion

TRIAL Holdings Inc. reported strong sales growth driven by daily necessities and outdoor items, despite a decline in alcoholic beverage sales due to prior demand surges. The company continues to expand its store network, opening a new supercenter in Miyazaki Prefecture, contributing to its robust market positioning.